Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B G Pollock

Showing results (31-40 of 127) with videos related to

Pageof 13
Sort By:
Journal of Clinical Psychopharmacology|April 19, 2000
Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatmentB G Pollock, F Laghrissi-Thode, W R Wagner
Journal of the National Cancer Institute|October 5, 1988
Regression models in clinical studies: determining relationships between predictors and responseF E Harrell, K L Lee, B G Pollock
Journal of Geriatric Psychiatry and Neurology|October 1, 1990
Pharmacodynamic issues relevant to geriatric psychopharmacologyB G Pollock, J M Perel, C F Reynolds
Psychopharmacology Bulletin|January 1, 1993
Nortriptyline in the hospitalized elderly: tolerance and side effect reductionJ Rosen, R Sweet, B G Pollock, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|May 23, 1997
Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detectionJ P Foglia, D Sorisio, M Kirshner, et al.
Psychopharmacology Bulletin|January 1, 1996
Paroxetine is a novel nitric oxide synthase inhibitorM S Finkel, F Laghrissi-Thode, B G Pollock, et al.
Journal of Geriatric Psychiatry and Neurology|July 1, 1994
Clomipramine in the elderly: tolerance and plasma levelsM E Kunik, B G Pollock, J M Perel, et al.
The Journal of Clinical Psychiatry|October 8, 1999
Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 yearsG Walters, C F Reynolds, B H Mulsant, et al.
Therapeutic Drug Monitoring|October 1, 1996
Bupropion plasma levels and CYP2D6 phenotypeB G Pollock, R A Sweet, M Kirshner, et al.
Clinical Pharmacology and Therapeutics|September 19, 2009
Predicting age-specific dosing of antipsychoticsH Uchida, B G Pollock, R R Bies, et al.
Pageof 13

Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
Journal of Clinical Psychopharmacology|April 19, 2000
Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatmentB G Pollock, F Laghrissi-Thode, W R Wagner
Journal of the National Cancer Institute|October 5, 1988
Regression models in clinical studies: determining relationships between predictors and responseF E Harrell, K L Lee, B G Pollock
Journal of Geriatric Psychiatry and Neurology|October 1, 1990
Pharmacodynamic issues relevant to geriatric psychopharmacologyB G Pollock, J M Perel, C F Reynolds
Psychopharmacology Bulletin|January 1, 1993
Nortriptyline in the hospitalized elderly: tolerance and side effect reductionJ Rosen, R Sweet, B G Pollock, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|May 23, 1997
Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detectionJ P Foglia, D Sorisio, M Kirshner, et al.
Psychopharmacology Bulletin|January 1, 1996
Paroxetine is a novel nitric oxide synthase inhibitorM S Finkel, F Laghrissi-Thode, B G Pollock, et al.
Journal of Geriatric Psychiatry and Neurology|July 1, 1994
Clomipramine in the elderly: tolerance and plasma levelsM E Kunik, B G Pollock, J M Perel, et al.
The Journal of Clinical Psychiatry|October 8, 1999
Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 yearsG Walters, C F Reynolds, B H Mulsant, et al.
Therapeutic Drug Monitoring|October 1, 1996
Bupropion plasma levels and CYP2D6 phenotypeB G Pollock, R A Sweet, M Kirshner, et al.
Clinical Pharmacology and Therapeutics|September 19, 2009
Predicting age-specific dosing of antipsychoticsH Uchida, B G Pollock, R R Bies, et al.
Pageof 13